Cargando…

What determines inclusion in the early phase of the type 2 diabetes care trajectory in Belgium?

BACKGROUND: In 2009, the Belgian National Institute of Health and Disability Insurance established a care trajectory (CT) for a subgroup of type 2 diabetes mellitus patients (T2DM) based on Wagner’s chronic care model. The goal of this CT is to optimise the quality of care using an integrated multid...

Descripción completa

Detalles Bibliográficos
Autores principales: Vanthomme, Katrien, Bossuyt, Nathalie, Moreels, Sarah, Boffin, Nicole, De Clercq, Etienne, Goderis, Geert, Van Casteren, Viviane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4166024/
https://www.ncbi.nlm.nih.gov/pubmed/25232479
http://dx.doi.org/10.1186/2049-3258-72-29
_version_ 1782335188879015936
author Vanthomme, Katrien
Bossuyt, Nathalie
Moreels, Sarah
Boffin, Nicole
De Clercq, Etienne
Goderis, Geert
Van Casteren, Viviane
author_facet Vanthomme, Katrien
Bossuyt, Nathalie
Moreels, Sarah
Boffin, Nicole
De Clercq, Etienne
Goderis, Geert
Van Casteren, Viviane
author_sort Vanthomme, Katrien
collection PubMed
description BACKGROUND: In 2009, the Belgian National Institute of Health and Disability Insurance established a care trajectory (CT) for a subgroup of type 2 diabetes mellitus patients (T2DM) based on Wagner’s chronic care model. The goal of this CT is to optimise the quality of care using an integrated multidisciplinary approach. This study aims to identify patient-related factors associated with inclusion in a CT and to determine the most frequent reasons for non-inclusion. METHODS: In 2010, the Belgian Sentinel Network of General Practices conducted a prevalence study of type 2 diabetes. The surveillance study carried out by this nationwide, representative network collected unique information about eligibility for the CT, inclusion in the CT and reasons for non-inclusion. Based on the official inclusion and exclusion criteria, we first identified a group of eligible patients. Within this group, we then calculated the proportion of patients included in a CT as well as the prevalence of reasons for non-inclusion as reported by GPs. Furthermore, bivariate associations between patient-level parameters and inclusion were analysed. Finally, any patient-level parameters found to be statistically significant were included in a multivariate logistic regression model. RESULTS: The 2010 study recorded 4600 Belgian type 2 diabetes patients. According to the official criteria, 589 patients were eligible for inclusion in a CT T2DM. By the end of August 2011, 95 patients had been included in a CT T2DM. Our findings reveal that the younger the eligible patient was, the more likely he or she was to be included in a CT. Patients living in Flanders were more likely to be included in the CT than were patients living in Wallonia. Motivated patients with specific plans to change their diets were also more likely to be included in a CT. The two most frequently reported reasons for non-inclusion were participation in another diabetes care programme and the timing of this surveillance study (inclusion will take place in the near future). CONCLUSIONS: Eligible diabetes patients who were admitted to a CT T2DM during the early phases of CT implementation were mainly found to be those who are able to make progress in their disease trajectories. In the future, more attention could be paid to also include more high-risk patients.
format Online
Article
Text
id pubmed-4166024
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-41660242014-09-18 What determines inclusion in the early phase of the type 2 diabetes care trajectory in Belgium? Vanthomme, Katrien Bossuyt, Nathalie Moreels, Sarah Boffin, Nicole De Clercq, Etienne Goderis, Geert Van Casteren, Viviane Arch Public Health Research BACKGROUND: In 2009, the Belgian National Institute of Health and Disability Insurance established a care trajectory (CT) for a subgroup of type 2 diabetes mellitus patients (T2DM) based on Wagner’s chronic care model. The goal of this CT is to optimise the quality of care using an integrated multidisciplinary approach. This study aims to identify patient-related factors associated with inclusion in a CT and to determine the most frequent reasons for non-inclusion. METHODS: In 2010, the Belgian Sentinel Network of General Practices conducted a prevalence study of type 2 diabetes. The surveillance study carried out by this nationwide, representative network collected unique information about eligibility for the CT, inclusion in the CT and reasons for non-inclusion. Based on the official inclusion and exclusion criteria, we first identified a group of eligible patients. Within this group, we then calculated the proportion of patients included in a CT as well as the prevalence of reasons for non-inclusion as reported by GPs. Furthermore, bivariate associations between patient-level parameters and inclusion were analysed. Finally, any patient-level parameters found to be statistically significant were included in a multivariate logistic regression model. RESULTS: The 2010 study recorded 4600 Belgian type 2 diabetes patients. According to the official criteria, 589 patients were eligible for inclusion in a CT T2DM. By the end of August 2011, 95 patients had been included in a CT T2DM. Our findings reveal that the younger the eligible patient was, the more likely he or she was to be included in a CT. Patients living in Flanders were more likely to be included in the CT than were patients living in Wallonia. Motivated patients with specific plans to change their diets were also more likely to be included in a CT. The two most frequently reported reasons for non-inclusion were participation in another diabetes care programme and the timing of this surveillance study (inclusion will take place in the near future). CONCLUSIONS: Eligible diabetes patients who were admitted to a CT T2DM during the early phases of CT implementation were mainly found to be those who are able to make progress in their disease trajectories. In the future, more attention could be paid to also include more high-risk patients. BioMed Central 2014-08-25 /pmc/articles/PMC4166024/ /pubmed/25232479 http://dx.doi.org/10.1186/2049-3258-72-29 Text en Copyright © 2014 Vanthomme et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Vanthomme, Katrien
Bossuyt, Nathalie
Moreels, Sarah
Boffin, Nicole
De Clercq, Etienne
Goderis, Geert
Van Casteren, Viviane
What determines inclusion in the early phase of the type 2 diabetes care trajectory in Belgium?
title What determines inclusion in the early phase of the type 2 diabetes care trajectory in Belgium?
title_full What determines inclusion in the early phase of the type 2 diabetes care trajectory in Belgium?
title_fullStr What determines inclusion in the early phase of the type 2 diabetes care trajectory in Belgium?
title_full_unstemmed What determines inclusion in the early phase of the type 2 diabetes care trajectory in Belgium?
title_short What determines inclusion in the early phase of the type 2 diabetes care trajectory in Belgium?
title_sort what determines inclusion in the early phase of the type 2 diabetes care trajectory in belgium?
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4166024/
https://www.ncbi.nlm.nih.gov/pubmed/25232479
http://dx.doi.org/10.1186/2049-3258-72-29
work_keys_str_mv AT vanthommekatrien whatdeterminesinclusionintheearlyphaseofthetype2diabetescaretrajectoryinbelgium
AT bossuytnathalie whatdeterminesinclusionintheearlyphaseofthetype2diabetescaretrajectoryinbelgium
AT moreelssarah whatdeterminesinclusionintheearlyphaseofthetype2diabetescaretrajectoryinbelgium
AT boffinnicole whatdeterminesinclusionintheearlyphaseofthetype2diabetescaretrajectoryinbelgium
AT declercqetienne whatdeterminesinclusionintheearlyphaseofthetype2diabetescaretrajectoryinbelgium
AT goderisgeert whatdeterminesinclusionintheearlyphaseofthetype2diabetescaretrajectoryinbelgium
AT vancasterenviviane whatdeterminesinclusionintheearlyphaseofthetype2diabetescaretrajectoryinbelgium